NCT00899418已完成不适用
Differential Response of Breast Cancer Patients on E2100 Treated With Bevacizumab as a Function of Genetic Polymorphisms of VEGF and KDR
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 500
- 主要终点
- Time to progression in patients with a known polymorphism vs those with wild-type vascular endothelial growth factor (VEGF) gene
研究概览
简要总结
RATIONALE: Studying samples of tumor tissue from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer. It may also help doctors understand how well patients respond to treatment.
PURPOSE: This laboratory study is examining tumor tissue samples from patients with breast cancer treated with bevacizumab on clinical trial ECOG-2100 to learn more about DNA changes and response in these patients.
详细描述
OBJECTIVES:
Primary
- Assess the effect of known variant polymorphisms (with functionally important associations) of the vascular endothelial growth factor (VEGF) gene on outcome (time to progression) in patients with breast cancer treated with bevacizumab on clinical trial ECOG-2100.
Secondary
- Assess the effect of known variant polymorphisms (with functionally important associations) of the VEGF receptor-2 (KDR) gene on outcome (time to progression) in these patients.
- Assess the effect of known variant polymorphisms of these genes on efficacy (objective response rate and survival) in these patients.
- Assess the effect of known variant polymorphisms of these genes on toxicity outcome in these patients.
- Assess the effect of VEGF polymorphisms on VEGF expression by immunohistochemical staining (a known prognostic marker).
- Assess the effect of KDR polymorphisms on KDR expression by immunohistochemical staining.
研究设计
- 研究类型
- Observational
- 时间视角
- Retrospective
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- Female
- 接受健康志愿者
- 否
入选标准
- 未提供
排除标准
- 未提供
结局指标
主要结局
Time to progression in patients with a known polymorphism vs those with wild-type vascular endothelial growth factor (VEGF) gene
次要结局
- Time to progression in patients with a known polymorphism vs those with wild-type VEGF receptor-2 (KDR) gene
- Difference in response rate, survival, and toxicity in patients with a known polymorphism vs wild-type VEGF and KDR
研究者
相似试验
已完成
不适用
SWOG 8897-A DNA Analysis in Predicting Treatment Outcome in Women With Breast Cancer in SWOG 8897Breast CancerNCT00896623SWOG Cancer Research Network1,577
已完成
不适用
Studying Cells Collected Through Ductal Lavage in Women Undergoing Surgery for Ductal Carcinoma In Situ or Other Breast CancerBreast CancerNCT00896857Wake Forest University Health Sciences30
已完成
不适用
Study of Estrogen Levels in Premenopausal Women Who Have Undergone Surgery for Breast Cancer and Are Receiving Triptorelin and Tamoxifen Citrate or Exemestane on Clinical Trial IBCSG 24-02Breast CancerNCT00975676ETOP IBCSG Partners Foundation123
已完成
不适用
Biomarkers in Young Patients With NeuroblastomaNeuroblastomaNCT01169376Children's Oncology Group380
已完成
不适用
Studying Biopsy Samples in Women Undergoing First-Line Chemotherapy for Metastatic Breast CancerBreast CancerNCT00870168Centre Jean Perrin60